General Information of Drug (ID: DMCPUKG)

Drug Name
BAY 85-8501 Drug Info
Indication
Disease Entry ICD 11 Status REF
Bronchiectasis CA24 Phase 2 [1]
Cross-matching ID
PubChem CID
66601502
CAS Number
CAS 1161921-82-9
TTD Drug ID
DMCPUKG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Neutrophil elastase (NE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sivelestat sodium hydrate DMOSJD0 Acute lung injury NB32.3 Phase 4 [3]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [4]
Sivelestat DM6BZCV Crohn disease DD70 Phase 3 [5]
Tiprelestat DM1SB94 Myocardial infarction BA41-BA43 Phase 2 [6]
AZD9668 DMB87M3 Bronchiectasis CA24 Phase 2 [7]
L-694,458 DMA0DSJ Cystic fibrosis CA25 Phase 2 [8]
DX-890 DMBFZET Acute lung injury NB32.3 Phase 2 [3]
POL-6014 DM9B68S Cystic fibrosis CA25 Phase 1 [9]
AZD-9819 DMWYHXG Chronic obstructive pulmonary disease CA22 Phase 1 [10]
BI 1323495 DMAUKTS Chronic obstructive pulmonary disease CA22 Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neutrophil elastase (NE) TTPLTSQ ELNE_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037600)
2 Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73.
3 Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77.
4 Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5.
5 Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203.
6 Company report (Proteo Biotech AG)
7 Clinical pipeline report, company report or official report of AstraZeneca (2009).
8 Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358).
10 Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9.
11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight